[go: up one dir, main page]

PE20081400A1 - Sintesis de compuestos de pirrolidina - Google Patents

Sintesis de compuestos de pirrolidina

Info

Publication number
PE20081400A1
PE20081400A1 PE2008000034A PE2008000034A PE20081400A1 PE 20081400 A1 PE20081400 A1 PE 20081400A1 PE 2008000034 A PE2008000034 A PE 2008000034A PE 2008000034 A PE2008000034 A PE 2008000034A PE 20081400 A1 PE20081400 A1 PE 20081400A1
Authority
PE
Peru
Prior art keywords
alkyl
compound
formula
aryl
iii
Prior art date
Application number
PE2008000034A
Other languages
English (en)
Inventor
Asaf Ragim Alimardanov
Lalitha Krishnan
Maotang Zhou
Ting-Zhong Wang
Jianxin Ren
John L Considine
Charles C Wu
Jason Brazzillo
Panolil Raveendranath
Karen Sutherland
Mahmoud Mirmehrabi
Subodh Deshmukh
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081400A1 publication Critical patent/PE20081400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, ALQUILO(C1-C6) O C(O)R5, EN DONDE R5 ES ARILO(C6-C10), ALQUILO(C1-C20), CICLOALQUILO(C3-C10), ENTRE OTROS; W ES ALQUILENO(C1-C6); R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6), C(O)OR6 O C(O)R9, EN DONDE R6 ES ALQUILO(C1-C20); R9 ES H, ARILO(C6-C10), ALQUILO(C1-C20), ENTRE OTROS; EL CUAL COMPRENDE: A) HACER REACCIONAR UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (IV) EN PRESENCIA DE UN AGENTE DE ACOPLAMIENTO TAL COMO DICICLOHEXILCARBODIIMIDA Y UN RESTO HIDROXILADO TAL COMO N-HIDROXIBENZOTRIAZOL PARA OBTENER UN COMPUESTO DE FORMULA (III) DONDE R7 ES H O ALQUILO(C1-C6); B) HACER REACCIONAR EL COMPUESTO DE FORMULA (III) CON UN HIDROXIDO DE METAL TAL COMO NaOH, KOH O LiOH EN PRESENCIA DE UN DISOLVENTE TAL COMO UNA MEZCLA DE AGUA Y ALCOHOL(C1-C3) A UNA TEMPERATURA DE -10ºC A 5ºC PARA OBTENER EL COMPUESTO DE FORMULA (I). ES UN COMPUESTO PREFERIDO: HIDROCLORURO DEL ACIDO (2S,4R)-1-(2-AMINOACETIL)-4-BENZAMIDOPIRROLIDINA-2-CARBOXILICO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS, INCONTINENCIA DE VEJIGA, DIABETES, ATEROSCLEROSIS
PE2008000034A 2006-12-21 2008-01-02 Sintesis de compuestos de pirrolidina PE20081400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87629006P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
PE20081400A1 true PE20081400A1 (es) 2008-10-24

Family

ID=39470360

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000034A PE20081400A1 (es) 2006-12-21 2008-01-02 Sintesis de compuestos de pirrolidina

Country Status (9)

Country Link
US (4) US20080188545A1 (es)
EP (2) EP2074087A2 (es)
AR (1) AR064626A1 (es)
DK (1) DK2468724T3 (es)
ES (1) ES2558856T3 (es)
PE (1) PE20081400A1 (es)
PL (1) PL2468724T3 (es)
TW (1) TW200833660A (es)
WO (1) WO2008079266A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386539B1 (en) 2005-12-23 2016-07-20 Zealand Pharma A/S 4-Aminoproline derivatives useful as lysine mimetics
ES2558856T3 (es) 2006-12-21 2016-02-09 Zealand Pharma A/S Síntesis de compuestos de pirrolidina
CN101863817A (zh) * 2009-06-09 2010-10-20 大连凯飞精细化工有限公司 (2s,4r)-4-氨基吡咯啉-1,2-二羧酸-1-叔丁酯-2-甲酯盐酸盐的制法
CN103333094B (zh) * 2013-06-19 2015-05-13 广东肇庆星湖生物科技股份有限公司 一种脯氨酸结晶精制的工艺方法
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
CN112142823B (zh) * 2019-06-28 2022-08-05 深圳翰宇药业股份有限公司 一种zp-1609的合成方法
EP3904339A1 (en) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Alkylaminoproline derivatives as alfa-2-delta-1 blockers
EP4291178A1 (en) 2021-02-10 2023-12-20 Breye Therapeutics ApS Danegaptide for use in the treatment or prevention of a kidney disease
CA3240515A1 (en) 2021-12-22 2023-06-29 Breye Therapeutics Aps Gap junction modulators and their use for the treatment of age-related macular degeneration
WO2025229109A1 (en) 2024-05-01 2025-11-06 Breye Therapeutics Aps Danegaptide compositions, processes, and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5784223A (en) 1980-11-13 1982-05-26 Nissan Motor Co Ltd Vibration absorber of vehicle
US4462943A (en) 1980-11-24 1984-07-31 E. R. Squibb & Sons, Inc. Carboxyalkyl amino acid derivatives of various substituted prolines
ATE22692T1 (de) 1981-08-03 1986-10-15 Squibb & Sons Inc Phosphonamidate verbindungen.
US4514391A (en) 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4560506A (en) 1984-05-25 1985-12-24 E. R. Squibb & Sons, Inc. Mercaptocycloalkylcarbonyl and mercaptoarylcarbonyl dipeptides
EP0175266B1 (en) * 1984-09-12 1996-03-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antihypertensive derivatives
JPS61148198A (ja) * 1984-12-22 1986-07-05 Ajinomoto Co Inc 新規トリペプチド化合物および甘味剤
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4849525A (en) 1987-09-21 1989-07-18 E. R. Squibb & Sons, Inc. Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
FR2700166B1 (fr) * 1993-01-07 1995-02-17 Rhone Poulenc Rorer Sa Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
DE4408531A1 (de) 1994-03-14 1995-09-28 Hoechst Ag PNA-Synthese unter Verwendung einer gegen schwache Säuren labilen Amino-Schutzgruppe
US5491164A (en) 1994-09-29 1996-02-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
AU4342097A (en) 1996-09-13 1998-04-02 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
AU5599898A (en) 1996-12-12 1998-07-03 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP2001513565A (ja) 1997-08-22 2001-09-04 科研製薬株式会社 新規なアミド誘導体
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
PL354998A1 (en) 1999-07-28 2004-03-22 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
IL148972A0 (en) 1999-10-14 2002-11-10 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2003535034A (ja) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
AU781674B2 (en) 2000-02-23 2005-06-02 Zealand Pharma A/S Novel antiarrhythmic peptides
AU2001251147A1 (en) 2000-03-31 2001-10-15 Dupont Pharmaceuticals Company Succinoylamino heterocycles as inhibitors of abeta protein production
EP1276717A2 (en) 2000-04-17 2003-01-22 Idun Pharmaceuticals, Inc. Inhibitors of the ice/ced-3 family of cysteine proteases
WO2001083517A1 (en) 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
NZ523782A (en) 2000-07-21 2005-10-28 Dendreon Corp Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
DK1387674T3 (en) 2000-10-13 2017-04-10 Curis Inc Hedgehog antagonists, methods and uses related thereto
FR2816838B1 (fr) * 2000-11-17 2004-12-03 Oreal Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
JP2005506295A (ja) 2001-02-22 2005-03-03 ジーランド ファーマ アクティーゼルスカブ 細胞間連絡促進化合物の新規医薬使用
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
ATE443703T1 (de) 2002-01-23 2009-10-15 Schering Corp Prolinderivate als ns3-serine protease hemmer, zur verwendung bei der bekämpfung von hepatitis c virusinfektion
US20030232788A1 (en) 2002-02-08 2003-12-18 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
JP4541882B2 (ja) 2002-07-02 2010-09-08 ノバルティス アーゲー Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
PL372826A1 (en) * 2002-07-26 2005-08-08 Altana Pharma Ag Pyrrolidine derivatives as tryptase inhibitors
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004087646A2 (de) 2003-04-03 2004-10-14 Merck Patent Gmbh Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
US20040229848A1 (en) 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
SI21507A (sl) * 2003-05-16 2004-12-31 LEK farmacevtska dru�ba d.d. Postopek za pripravo spojin z ace inhibitornim delovanjem
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
CN1528745A (zh) 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
WO2005085197A1 (en) 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
ES2367576T3 (es) * 2004-03-15 2011-11-04 Janssen Pharmaceutica Nv Nuevos compuestos como moduladores de receptores opioides.
GEP20104926B (en) 2004-03-30 2010-03-25 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
BRPI0513426A (pt) 2004-07-16 2007-11-27 Gilead Sciences Inc processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
EP2386539B1 (en) * 2005-12-23 2016-07-20 Zealand Pharma A/S 4-Aminoproline derivatives useful as lysine mimetics
ES2558856T3 (es) 2006-12-21 2016-02-09 Zealand Pharma A/S Síntesis de compuestos de pirrolidina

Also Published As

Publication number Publication date
US20150322007A1 (en) 2015-11-12
ES2558856T3 (es) 2016-02-09
WO2008079266A3 (en) 2008-11-06
PL2468724T3 (pl) 2016-05-31
EP2468724B1 (en) 2015-11-18
US20130053344A1 (en) 2013-02-28
DK2468724T3 (en) 2016-02-22
AR064626A1 (es) 2009-04-15
WO2008079266A2 (en) 2008-07-03
US8927590B2 (en) 2015-01-06
US9469609B2 (en) 2016-10-18
EP2074087A2 (en) 2009-07-01
TW200833660A (en) 2008-08-16
EP2468724A1 (en) 2012-06-27
US20080188545A1 (en) 2008-08-07
US20100249207A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
PE20081400A1 (es) Sintesis de compuestos de pirrolidina
US8143427B2 (en) Method for producing aminoacetylpyrrolidinecarbonitrile derivative
PE20081387A1 (es) Proceso de preparacion del acido 1-(2-etil-butil)-ciclohexanocarboxilico
PE20091519A1 (es) Derivados de bencimidazol sustituido por carboxilo o por hidroxilo
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CO6382182A2 (es) Proceso para la preparación de benzonorbornen-5-il-amidas del ácido pirazolil-4-carboxílico.
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
AR055057A1 (es) Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria.
UA109883C2 (uk) Спосіб отримання сполук для застосування як інгібіторів sglt2
EA200970307A1 (ru) Способ получения галогенидов n-алкилнальтрексона
UY30387A1 (es) Nuevos compuestos
ES2421537T3 (es) Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
CO6160240A2 (es) Proceso de sintesis de macrolida
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
MX2009003823A (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas.
AR063415A1 (es) Hidratos de clorhidrato de erlotinib para el tratamiento del cancer
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
CO6110143A1 (es) Nuevo procedimiento de sintesis del ranelato de estroncio y de sus hidratos
MA33027B1 (fr) Nouveau procede de synthese de l'ivabradine zet de ses sels d'addition a un acide pharmaceutiquement acceptable
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
RU2011124888A (ru) Способ получения йодированного контрастного агента
AR069319A1 (es) Metodo para preparar capecitabina y compuesto intermediario de trialquil carbonato.

Legal Events

Date Code Title Description
FX Voluntary withdrawal